<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00052273</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000258138</org_study_id>
    <secondary_id>UCLA-0206061</secondary_id>
    <secondary_id>LILLY-H6Q-MC-JCAH</secondary_id>
    <secondary_id>NCI-G02-2132</secondary_id>
    <nct_id>NCT00052273</nct_id>
  </id_info>
  <brief_title>LY317615 Plus Capecitabine in Treating Patients With Advanced Solid Tumors</brief_title>
  <official_title>A Phase I Dose Escalation Study With Oral LY317615 in Combination With Capecitabine in Advanced Cancer Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jonsson Comprehensive Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Jonsson Comprehensive Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: LY317615 may stop the growth of cancer cells by blocking the enzymes necessary for&#xD;
      cancer cell growth and by stopping blood flow to the tumor. Drugs used in chemotherapy use&#xD;
      different ways to stop tumor cells from dividing so they stop growing or die. Combining&#xD;
      LY317615 with capecitabine may kill more tumor cells.&#xD;
&#xD;
      PURPOSE: Phase I trial to study the effectiveness of combining LY317615 with capecitabine in&#xD;
      treating patients who have advanced solid tumors.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the maximum tolerated dose and the recommended phase II dose of LY317615 and&#xD;
           capecitabine in patients with advanced solid tumors.&#xD;
&#xD;
        -  Determine the safety profile of this regimen in these patients.&#xD;
&#xD;
        -  Determine the pharmacokinetics of this regimen in these patients.&#xD;
&#xD;
        -  Determine, preliminarily, the antitumor activity of this regimen in these patients.&#xD;
&#xD;
        -  Determine the effects of LY317615 on potential angiogenic surrogate markers in these&#xD;
           patients.&#xD;
&#xD;
      OUTLINE: This is a dose-escalation study.&#xD;
&#xD;
      Patients receive oral LY317615 daily on days 1-14 (course 1 only). Beginning with course 2,&#xD;
      patients receive oral LY317615 daily on days 1-21 and oral capecitabine twice daily on days&#xD;
      1-14. Courses repeat every 21 days in the absence of disease progression or unacceptable&#xD;
      toxicity.&#xD;
&#xD;
      Cohorts of 3-6 patients receive escalating doses of LY317615 and capecitabine until the&#xD;
      maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at&#xD;
      which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Once the MTD is&#xD;
      determined, additional patients are treated at the recommended phase II dose.&#xD;
&#xD;
      Patients are followed at 30 days after the last dose of study drug.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 12-36 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2002</start_date>
  <completion_date type="Actual">October 2005</completion_date>
  <primary_completion_date type="Actual">November 2004</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment type="Actual">16</enrollment>
  <condition>Adult</condition>
  <condition>Solid Tumor</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>capecitabine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>enzastaurin hydrochloride</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically confirmed solid tumor that is refractory to standard therapy or for&#xD;
             which no standard therapy exists&#xD;
&#xD;
          -  Measurable or evaluable disease&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
          -  ECOG 0-2&#xD;
&#xD;
          -  Hematopoietic&#xD;
&#xD;
               -  Absolute neutrophil count at least 1,500/mm^3&#xD;
&#xD;
               -  Platelet count at least 100,000/mm^3&#xD;
&#xD;
               -  Hemoglobin at least 9 g/dL (erythrocyte transfusions allowed)&#xD;
&#xD;
          -  Hepatic&#xD;
&#xD;
               -  Bilirubin no greater than 1.5 times upper limit of normal (ULN)&#xD;
&#xD;
               -  ALT and AST no greater than 2.5 times ULN (5 times ULN if liver metastases&#xD;
                  present)&#xD;
&#xD;
          -  Renal&#xD;
&#xD;
               -  Creatinine clearance at least 50 mL/min&#xD;
&#xD;
               -  Potassium at least 3.4 mEq/L&#xD;
&#xD;
               -  Calcium at least 8.4 mg/dL&#xD;
&#xD;
               -  Magnesium at least 1.2 mEq/L&#xD;
&#xD;
          -  Cardiovascular&#xD;
&#xD;
               -  QTc interval no greater than 450 msec in males&#xD;
&#xD;
               -  QTc interval no greater than 470 msec in females&#xD;
&#xD;
               -  No other electrocardiogram abnormalities&#xD;
&#xD;
          -  Able to swallow capsules&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception during and for 3-6 months after&#xD;
             study&#xD;
&#xD;
          -  Endocrine therapy&#xD;
&#xD;
               -  At least 4 weeks since prior anticancer hormonal therapy&#xD;
&#xD;
               -  At least 6 weeks since prior bicalutamide&#xD;
&#xD;
               -  At least 4 weeks since prior flutamide or nilutamide&#xD;
&#xD;
               -  Concurrent luteinizing hormone-releasing hormone analog therapy (e.g., leuprolide&#xD;
                  or goserelin) allowed for patients with prostate cancer if started before study&#xD;
                  entry&#xD;
&#xD;
          -  At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin).&#xD;
&#xD;
          -  Radiotherapy&#xD;
&#xD;
               -  At least 4 weeks since prior radiotherapy&#xD;
&#xD;
               -  At least 2 weeks since prior palliative radiotherapy&#xD;
&#xD;
               -  Recovered from prior therapy&#xD;
&#xD;
          -  Other&#xD;
&#xD;
               -  At least 4 weeks since prior investigational anticancer therapy&#xD;
&#xD;
               -  At least 4 weeks since other prior anticancer therapy&#xD;
&#xD;
               -  At least 30 days since prior experimental drugs&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  known untreated or symptomatic CNS metastases&#xD;
&#xD;
          -  concurrent hematologic malignancies&#xD;
&#xD;
          -  gastrointestinal disorder that would interfere with oral drug absorption&#xD;
&#xD;
          -  serious concurrent systemic disorder&#xD;
&#xD;
          -  compliance issues that would preclude study&#xD;
&#xD;
          -  geographical conditions that would preclude study&#xD;
&#xD;
          -  active infection&#xD;
&#xD;
          -  prior hypersensitivity to any component of study drugs&#xD;
&#xD;
          -  pregnant or nursing&#xD;
&#xD;
          -  concurrent immunotherapy&#xD;
&#xD;
          -  concurrent routine filgrastim (G-CSF)&#xD;
&#xD;
          -  other concurrent chemotherapy&#xD;
&#xD;
          -  other concurrent hormonal therapy&#xD;
&#xD;
          -  concurrent radiotherapy (including palliative therapy)&#xD;
&#xD;
          -  other concurrent experimental medications&#xD;
&#xD;
          -  other concurrent anticancer therapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carolyn Britten, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Jonsson Comprehensive Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Jonsson Comprehensive Cancer Center, UCLA</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095-1781</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2012</verification_date>
  <study_first_submitted>January 24, 2003</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>July 30, 2020</last_update_submitted>
  <last_update_submitted_qc>July 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 3, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>unspecified adult solid tumor</keyword>
  <keyword>protocol specific</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Capecitabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

